A pregnant patient with ALK-positive non-small cell lung cancer treated with alectinib

Standard

A pregnant patient with ALK-positive non-small cell lung cancer treated with alectinib : A case report and review of the literature. / de Smedt, Fabian; Dessy, Frédérique; Carestia, Luciano et al.

In: Oncology letters, Vol. 25, No. 2, 13640, 01.02.2023.

Research output: Contribution to journal › Review article › Academic › peer-review

Harvard

de Smedt, F, Dessy, F, Carestia, L, Baldin, P, Nana, FA, Clapuyt, P, Boon, VR, Amant, F & Gziri, MM 2023, 'A pregnant patient with ALK-positive non-small cell lung cancer treated with alectinib: A case report and review of the literature', Oncology letters, vol. 25, no. 2, 13640. https://doi.org/10.3892/ol.2022.13640

APA

de Smedt, F., Dessy, F., Carestia, L., Baldin, P., Nana, F. A., Clapuyt, P., Boon, V. R., Amant, F., & Gziri, M. M. (2023). A pregnant patient with ALK-positive non-small cell lung cancer treated with alectinib: A case report and review of the literature. Oncology letters, 25(2), [13640]. https://doi.org/10.3892/ol.2022.13640

Vancouver

de Smedt F, Dessy F, Carestia L, Baldin P, Nana FA, Clapuyt P et al. A pregnant patient with ALK-positive non-small cell lung cancer treated with alectinib: A case report and review of the literature. Oncology letters. 2023 Feb 1;25(2):13640. doi: 10.3892/ol.2022.13640

Author

de Smedt, Fabian ; Dessy, Frédérique ; Carestia, Luciano et al. / A pregnant patient with ALK-positive non-small cell lung cancer treated with alectinib : A case report and review of the literature. In: Oncology letters. 2023 ; Vol. 25, No. 2.

BibTeX

@article{dc86a3732b96414aba958016bd96befd,

title = "A pregnant patient with ALK-positive non-small cell lung cancer treated with alectinib: A case report and review of the literature",

abstract = "Oncogenic rearrangements in the anaplastic lymphoma kinase (ALK) gene account for 5% of non-small cell lung cancer (NSCLC) cases. ALK inhibitors have markedly improved the outcome of metastatic ALK-positive NSCLC (ALK+ mNSCLC) by increasing long-term overall survival. Although a diagnosis of NSCLC during pregnancy or the peripartum period is rare, ALK+ NSCLC accounts for 38% of NSCLC cases in women of childbearing age (18-45 years old). The younger age and prolonged survival of patients with ALK+ mNSCLC bring new challenges for lung cancer and obstetrics research, and raises questions related to pregnancy and family planning. The present study described normal fetal development and no obstetric complications in a patient infected with HIV diagnosed with ALK+ mNSCLC, who became pregnant during treatment with alectinib, a third-generation ALK inhibitor.",

keywords = "alectinib, anaplastic lymphoma kinase gene, lung cancer, pregnancy",

author = "{de Smedt}, Fabian and Fr{\'e}d{\'e}rique Dessy and Luciano Carestia and Pamela Baldin and Nana, {Frank Aboubakar} and Philippe Clapuyt and Boon, {V. ronique} and Fr{\'e}d{\'e}ric Amant and Gziri, {Mina Mhallem}",

year = "2023",

month = feb,

day = "1",

doi = "10.3892/ol.2022.13640",

language = "English",

volume = "25",

journal = "Oncology letters",

issn = "1792-1074",

publisher = "Spandidos Publications",

number = "2",

}

RIS

TY - JOUR

T1 - A pregnant patient with ALK-positive non-small cell lung cancer treated with alectinib

T2 - A case report and review of the literature

AU - de Smedt, Fabian

AU - Dessy, Frédérique

AU - Carestia, Luciano

AU - Baldin, Pamela

AU - Nana, Frank Aboubakar

AU - Clapuyt, Philippe

AU - Boon, V. ronique

AU - Amant, Frédéric

AU - Gziri, Mina Mhallem

PY - 2023/2/1

Y1 - 2023/2/1

N2 - Oncogenic rearrangements in the anaplastic lymphoma kinase (ALK) gene account for 5% of non-small cell lung cancer (NSCLC) cases. ALK inhibitors have markedly improved the outcome of metastatic ALK-positive NSCLC (ALK+ mNSCLC) by increasing long-term overall survival. Although a diagnosis of NSCLC during pregnancy or the peripartum period is rare, ALK+ NSCLC accounts for 38% of NSCLC cases in women of childbearing age (18-45 years old). The younger age and prolonged survival of patients with ALK+ mNSCLC bring new challenges for lung cancer and obstetrics research, and raises questions related to pregnancy and family planning. The present study described normal fetal development and no obstetric complications in a patient infected with HIV diagnosed with ALK+ mNSCLC, who became pregnant during treatment with alectinib, a third-generation ALK inhibitor.

AB - Oncogenic rearrangements in the anaplastic lymphoma kinase (ALK) gene account for 5% of non-small cell lung cancer (NSCLC) cases. ALK inhibitors have markedly improved the outcome of metastatic ALK-positive NSCLC (ALK+ mNSCLC) by increasing long-term overall survival. Although a diagnosis of NSCLC during pregnancy or the peripartum period is rare, ALK+ NSCLC accounts for 38% of NSCLC cases in women of childbearing age (18-45 years old). The younger age and prolonged survival of patients with ALK+ mNSCLC bring new challenges for lung cancer and obstetrics research, and raises questions related to pregnancy and family planning. The present study described normal fetal development and no obstetric complications in a patient infected with HIV diagnosed with ALK+ mNSCLC, who became pregnant during treatment with alectinib, a third-generation ALK inhibitor.

KW - alectinib

KW - anaplastic lymphoma kinase gene

KW - lung cancer

KW - pregnancy

UR - http://www.scopus.com/inward/record.url?scp=85144536775&partnerID=8YFLogxK

U2 - 10.3892/ol.2022.13640

DO - 10.3892/ol.2022.13640

M3 - Review article

C2 - 36644155

VL - 25

JO - Oncology letters

JF - Oncology letters

SN - 1792-1074

IS - 2

M1 - 13640

ER -

ID: 29723936

Generic Portal